James Huang, Nabil Rizk, Bernard Park, Manjit Bains, Raja Flores, Robert Downey, Valerie Rusch; Thoracic Service, Memorial Sloan-Kettering Cancer Center, New York, NY
Objective: Extended resections for advanced-stage thymomas are uncommonly performed because of the potential morbidity in the face of unclear survival or palliative benefit. We reviewed our experience with multimodality treatment for Masaoka stage IVA thymomas for feasibility and outcomes.Methods: Retrospective review of a single institution surgical database. Data included patient demographics, pre-operative staging and treatment, peri-operative events, pathologic findings, and postoperative outcomes.
Results: During the 10 year period from 1996-2006, 115 thymic tumors were primarily resected, including 17 patients who had Masaoka stage IVA thymoma. Patient characteristics are listed in the table below. At a median follow-up of 28.8 months (range 4.6-103.5), 40% (7/17) are disease-free, 3 have died of disease, 5 are alive with disease and one was lost to follow-up. Median survival has not yet been reached. 3-year survival is 91%, and 5-year survival is 80%.
Conclusion: Multimodality therapy including extended surgical resection can be performed in select patients with Stage IVA thymoma with low morbidity and mortality and results in excellent long-term survival.
Back to Annual Meeting
Back to Program Outline
